GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kimia Biosciences Ltd (BOM:530313) » Definitions » Additional Paid-In Capital

Kimia Biosciences (BOM:530313) Additional Paid-In Capital : ₹0.00 Mil(As of . 20)


View and export this data going back to 2017. Start your Free Trial

What is Kimia Biosciences Additional Paid-In Capital?



Kimia Biosciences Additional Paid-In Capital Historical Data

The historical data trend for Kimia Biosciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kimia Biosciences Additional Paid-In Capital Chart

Kimia Biosciences Annual Data
Trend
Additional Paid-In Capital

Kimia Biosciences Semi-Annual Data
Additional Paid-In Capital

Kimia Biosciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Kimia Biosciences Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Kimia Biosciences's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Kimia Biosciences (BOM:530313) Business Description

Traded in Other Exchanges
N/A
Address
Netaji Subhash Place, 974, 9th Floor, Aggarwal Millenium Tower-II, Pitampura, New Delhi, IND, 110 034
Kimia Biosciences Ltd is a company engaged in the manufacturing of bulk drugs. Some of the company's products include Azelnidipine, Deflazacort, Oxaceprol, Seratodast, and Tretinoin among others. Its only operating segment being Pharmaceuticals.

Kimia Biosciences (BOM:530313) Headlines

No Headlines